Implantable Hearing solutions provider, Cochlear Limited (ASX: COH) registered 9% rise in revenue after the launch of worldâs first Made for iPhone cochlear implant sound processor, Nucleus 7. On Tuesday, 14 August 2018, the company released its results for financial year ending 30 June 2018.
Adjusted net profit of the company increased to $245.8 million, an increase of 10% on FY17, which was within the guidance range of $240-250 million. In FY18, sales revenue of the company grew 9% on the back of unit growth of 8% to 35,260 units with solid Cochlear implants unitâs growth in US and UK. The total sales revenue of $1.4 billion represents 48% of revenue from America region, 35% from Europe, Middle East and Africa region, and remaining 17% from Asia pacific. Company reported earnings per share of $4.27, up by 10%, as Earnings before interest and tax increased by $32.8 million to $348.4 million.
[optin-monster-shortcode id="wxhmli4jjedneglg1trq"]The business generated $258.1 million in operating cash flow, with free cash flow increasing to $202.7 million as compared to previous year. This gap of $55.3 million between operating cash flow and free cash flow is mainly attributable to capital expenditure of $42.0 million, driven by additional investment in plant and equipment and IT systems. Solid cash flow generation supported the 14% increase in the fully franked final dividend of $1.60 per security making a full year dividend of $3.00 per security, up 11%.
Chief executive Dig Howitt said the company expects an 8-12% increase to $265 million to $275 million in FY19, falling short of market expectation.
The company also announced that non-executive director Professor Edward Byrne has advised his intention to retire from Cochlear Limited Board at the end of next Annual General Meeting after serving for 16 years to the board.
Following to FY18 results announcement, COH shares dropped by $6.030 or 3% to $192.750 as investors found the result to be falling short of expectations.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
